๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Thyroxine Binding Globulin and Thyroid Function Tests in Patients with Hepatocellular Carcinoma

โœ Scribed by W. John Kalk; Michael C. Kew; Mervyn D. Danilewitz; Frederick Jacks; L. Andre Van Der Walt; Joseph Levin


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
524 KB
Volume
2
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

โœฆ Synopsis


To determine the prevalence of elevated serum concentrations of thyroxine binding globulin (TBG) in patients with hepatocellular carcinoma (HCC) and the influence of the associated cirrhosis, TBG was measured in 39 patients with HCC, 22 with and 17 without cirrhosis, in 20 patients with cryptogenic macronodular cirrhosis but without HCC, and in 40 matched controls. The mean serum TBG concentration in the patients was 34.5 +/- 17.7 microgram per ml, compared to 21.4 +/- 6.8 microgram pr ml in controls and 20.5 +/- 6.3 microgram per ml in cirrhosis without HCC (p less than 0.01). The presence or absence of cirrhosis in the HCC patients did not significantly influence the frequency with which elevated TBG levels were found; levels were normal in every subject with cirrhosis and no HCC. The mean thyroxine (T4): TBG ratio was 5.58 +/- 1.78 in controls and was reduced in HCC patients with both elevated (3.33 +/- 0.80, p less than 0.001) and normal TBG values (4.39 +/- 1.90, p less than 0.05), and in cirrhotics without HCC (4.29 +/- 1.01, p less than 0.01). T4 and TBG concentrations correlated significantly in controls, in HCC patients with elevated TBG, and in the cirrhotics without HCC. It is concluded that in patients with HCC (i) TBG levels may be elevated both in the presence or absence of cirrhosis; (ii) there is reduced binding of T4 TBG, and (iii) a low T4:TBG ratio excludes the diagnosis of hyperthyroidism in the presence of high T4 levels. TBG levels are normal in patients with cryptogenic macronodular cirrhosis without HCC.


๐Ÿ“œ SIMILAR VOLUMES


Impaired binding properties of thyroxine
โœ Winston L. Hutchinson; Yvette S. White; Elizabeth A. Fagan; Philip J. Johnson; R ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 539 KB

To determine the factors underlying the apparent reduction in binding ability of thyroxine-binding globulin in hepatocellular carcinoma, hormonebinding characteristics were further examined in patients with this disease and in control subjects. No differences in affinity constants with respect to tr

Depressed immune function in patients wi
โœ Toshiji Saibara; Takashi Maeda; Masako Miyazaki; Saburo Onishi; Yasutake Ymamot ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 521 KB

Hepatocellular carcinomas 1 cm in diameter with high or low echogenicity can be detected on ultrasonography and confirmed on fine-needle biopsy, but it is still very difficult to detect small hepatocellular carcinomas with isoechogenicity. In this study, we assessed lymphokine-activated killer cell

Screening tests for hepatocellular carci
โœ Kelly A. Gebo; Geetanjali Chander; Mollie W. Jenckes; Khalil G. Ghanem; H. Frank ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 951 KB

This systematic review addresses the following questions: (1) What is the efficacy of using screening tests for hepatocellular carcinoma (HCC) in improving outcomes in chronic hepatitis C, and (2) what are the sensitivity and specificity of screening tests for HCC in chronic hepatitis C? The search

Defective function of lymphokine-activat
โœ Toshiji Saibara; Saburo Onishi; Hiroshi Sakaeda; Yasutake Yamamoto ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 608 KB

Lymphokine-activated killer activity and natural killer activity in hepatocellular carcinoma patients were d. Maximum lymphokine-activated killer activity was induced at 3 to 6 days of incubation, and lymphokine-activated killer activity tended to increase in a manner dose dependent of recombinant i